Drug or treatment

Ofatumumab clinical trials

• 10Clinical trials
• 1New in 30 days
• 7Countries

Newest trials

All recruiting trials (10)

• Ofatumumab for drug-refractory Narcolepsy Type 1

  Aims to see if a single dose of ofatumumab helps people with Narcolepsy Type 1 who have not responded to previous treatments.

  Recruiting Phase 1/2 Xijing Hospital · Xi'an, Shaanxi · NCT07871006

• Comparing Ofatumumab vs Ocrelizumab in Real-World MS Care

  This real-world study tests whether ofatumumab works differently from ocrelizumab for people with multiple sclerosis.

  Recruiting Novartis · East Hanover, New Jersey · NCT07779460

• Switching to Ofatumumab: IgG Levels in People with MS

  A real-life study tests whether stopping ocrelizumab and starting ofatumumab changes IgG levels in adults with multiple sclerosis who have been on ocrelizumab for at least 18 months.

  Recruiting University Hospital, Lille · Lille · NCT07625800

• Ofatumumab treatment and blood neurofilament levels in relapsing multiple sclerosis

  This observational study will try ofatumumab in adults with relapsing MS to see if it is safe and whether blood neurofilament light chain (sNfL) levels change.

  Recruiting Third Affiliated Hospital, Sun Yat-Sen University · Guangzhou, Guangdong · NCT07353216

• Using eye movement biomarkers to track disease changes in active RRMS patients

  This study is testing if tracking eye movements can help doctors see how well a new treatment works for people with active Relapsing Remitting Multiple Sclerosis.

  Recruiting at 14 sites Phase 4 Novartis · Calgary, Alberta and 13 other locations · NCT06733922

• Observing the effects of Ofatumumab on Multiple Sclerosis in Greece

  This study is trying to see how well Ofatumumab works for adults with Relapsing Multiple Sclerosis in Greece over two years.

  Recruiting at 14 sites Novartis · Athens, Attica and 14 other locations · NCT06486779

• Observing the effects of Ofatumumab in Portuguese patients with relapsing multiple sclerosis

  This study is testing how well Ofatumumab works for Portuguese patients with relapsing multiple sclerosis who started treatment either within three years of their diagnosis or after, to see if it helps them stay symptom-free.

  Recruiting at 10 sites Novartis · Amadora and 9 other locations · NCT05809986

• Registry to track pregnancy outcomes in women using Kesimpta for MS

  This study is looking at how using Kesimpta during pregnancy affects women with multiple sclerosis and their babies to help understand its safety and outcomes.

  Recruiting Novartis · La Jolla, California · NCT05634967

• Ofatumumab for AQP4‑antibody positive neuromyelitis optica spectrum disorder

  This pilot will try ofatumumab, a human anti‑CD20 antibody, in adults with AQP4‑IgG positive NMOSD who have had recent relapses to see if it reduces relapses and is safe.

  Recruiting Phase 1/2 Tang-Du Hospital · Xi'an, Shaanxi · NCT05504694

• Observing people with relapsing MS who start approved injectable or selected oral disease-modifying treatments

  This project will test how approved injectable and certain oral MS treatments work for adults with relapsing MS receiving routine care in Germany.

  Recruiting at 78 sites Novartis · Albstadt, Baden-Wurttemberg and 140 other locations · NCT05344469

Quick answers

How many clinical trials of Ofatumumab are recruiting right now?

10, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 7 countries. The most sites are in China (3 trials), United States (2 trials), France (1 trial), Greece (1 trial), Germany (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1/2: 2, Phase 4: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →